ISRG - Intuitive Surgical, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
504.22
+13.81 (+2.82%)
At close: 4:00PM EDT

504.22 0.00 (0.00%)
After hours: 5:00PM EDT

Stock chart is not supported by your current browser
Previous Close490.41
Open490.00
Bid490.00 x 1200
Ask506.00 x 1200
Day's Range484.30 - 506.88
52 Week Range360.50 - 619.00
Volume821,366
Avg. Volume978,550
Market Cap58.868B
Beta (5Y Monthly)1.11
PE Ratio (TTM)43.69
EPS (TTM)11.54
Earnings DateApr 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est628.57
  • Still The No. 1 Rule For Stock Market Investors: Always Cut Your Losses Short
    Investor's Business Daily

    Still The No. 1 Rule For Stock Market Investors: Always Cut Your Losses Short

    In the battle for investment survival, you can learn a lot from judo. The first and most important lesson in that martial art is the same for the stock market: damage control.

  • Cramer Reveals Stock Favorites, Says Intuitive Surgical A 'Winner'
    Benzinga

    Cramer Reveals Stock Favorites, Says Intuitive Surgical A 'Winner'

    Answering questions from callers, former hedge fund manager and CNBC "Mad Money" host Jim Cramer revealed his favorite stock picks Thursday.5G Is KingSmartphone maker BlackBerry Ltd (NYSE: BB) is clearly not Cramer's favorite. Describing it as "absolutely nothing," he suggested a caller take their money if there's anything left and buy Marvell Technology Group Ltd (NASDAQ: MRVL) because "5G is king."Marvell Tech is engaged in the design, development and marketing of integrated circuits for communications-related markets.Another tech darling of Cramer's is Adobe Inc. (NASDAQ: ADBE)."Why not buy a big position in Adobe?" he said. "That company is great."Medical MarvelsGiven the coronavirus pandemic, it was no surprise that pharmaceutical and medical stocks were discussed.Cramer is positive on Intuitive Surgical Inc. (NASDAQ: ISRG) which he described as a "winner." The company develops, manufactures and markets robotic products used in minimally invasive surgeries. Their most well-known product is the da Vinci Surgical System."I love the product," he said of Intuitive Surgical. Cramer was equally upbeat discussing drugmakers Pfizer Inc. (NYSE: PFE) and Merck & Co., Inc. (NYSE: MRK).A Leap Of Faith And A GambleCramer's advice on Inovio Pharmaceuticals Inc.(NASDAQ: INO)?"So if you can handle the speculation, you can put one-twentieth of your money into it. No more than that." Inovio is in a race to create a vaccine for COVID-19.Cramer called it the most speculative of stocks that he discussed on the show Thursday.Another speculative pick he mentioned is Provention Bio Inc. (NASDAQ: PRVB). The company has paused its Phase 3 Type 1 diabetes drug trial.Expressing his faith in Penn National Gaming, Inc. (NASDAQ: PENN) and its celebrity founder Dave Portnoy, Cramer said he believes the pandemic will end and "Portnoy is going to come on top ... I believe in Penn National." He warned that it will not not happen fast because "of COVID."Penn National operates, owns or has interests in 39 gaming and racing facilities, as well as video game operations in the United States.An Invitation Is ExtendedSimon Property Group Inc. (NYSE: SPG) recently closed all its U.S. retail properties -- malls, premium outlets and mills -- due to the coronavirus pandemic. Cramer called out to David Simon, the company's chairman, "come on the show."Photo courtesy of Intuitive Surgical. See more from Benzinga * WWE's Wrestlemania 36 Takes Another Blow, Could Be Without Top Star Roman Reigns * US Surpasses China And Italy In Number Of Infected With COVID-19 * Huawei Releases Latest Flagship Phone Amid Global Coronavirus Lockdown(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • 5 Superstar Stocks on Sale During the Coronavirus Crisis
    Zacks

    5 Superstar Stocks on Sale During the Coronavirus Crisis

    Stocks are the only thing people won't buy when they go on sale. But with stocks in a bear market, now's your chance to pick up some of the best companies.

  • This Robotic Surgery Behemoth Hit A Speed Bump — Is ISRG Stock A Buy?
    Investor's Business Daily

    This Robotic Surgery Behemoth Hit A Speed Bump — Is ISRG Stock A Buy?

    ISRG stock has skidded this year, leading Intuitive Surgical stock performance to lag its peers in its medical technology group. So, is it time to take on this robotic surgery stock?

  • Finding Companies That Can Survive Hard Times
    GuruFocus.com

    Finding Companies That Can Survive Hard Times

    Strong balance sheets are a must-have, and brand names and other assets help Continue reading...

  • 6 Med-Tech and Medical-Device Stocks to Buy
    Kiplinger

    6 Med-Tech and Medical-Device Stocks to Buy

    Health care, which makes up nearly 18% of American GDP, has long been a fruitful hunting ground for investors seeking growth. And medical-tech and medical-device stocks have always been particularly compelling niches.Not only do these companies ride the coattails of inexorable health-care spending, but their commitment to research and development can create new industries that they can in turn dominate.It's not an easy time right now, of course. The COVID-19 outbreak has taken a chunk out of every sector and almost every industry, with only a few "coronavirus stocks" enjoying any meaningful gains. Medical devices have at least been better than the market, which has declined by about 29% in this bear market so far, as measured by the S&P; 500\. But the iShares U.S. Medical Devices ETF (IHI) still has been cut to the tune of 25% in the same time frame.That could provide investors with a chance to buy medical-device stocks and other med-tech plays at a significant discount, however. While their growth might be stunted in the short-term, their longer-term prospects are likely to improve again once the COVID-19 threat is contained - and a few are seeing additional business in the wake of the outbreak.Here, we look at six med-tech and medical-device stocks to buy. SEE ALSO: 10 Health and Pharmaceutical Companies Fighting the Coronavirus

  • Research and Development: A Twofer to Widen Moat and Fuel Growth
    GuruFocus.com

    Research and Development: A Twofer to Widen Moat and Fuel Growth

    A crucial point on the common stock checklist by the father of growth investing Continue reading...

  • Reuters

    Intuitive Surgical sees material impact to business as coronavirus spreads

    Intuitive Surgical Inc said on Monday it expects material impact on its financial results due to surgical procedure disruptions caused by the outbreak of the coronavirus. The maker of robotic surgical systems said the specific extent or duration of the outbreak's impact on its financial results cannot be predicted.

  • A Recap on Market Valuation
    GuruFocus.com

    A Recap on Market Valuation

    The Warren Buffett Indicator is still telling you not to bet on America Continue reading...

  • IBD's Investing Podcast: How To Make More Money In The Stock Market With Stock Charts
    Investor's Business Daily

    IBD's Investing Podcast: How To Make More Money In The Stock Market With Stock Charts

    Investing with IBD is a weekly podcast focused on helping investors learn how to make more money in the stock market by using stock charts to find top stocks.

  • Is Intuitive Surgical, Inc. (NASDAQ:ISRG) Overpaying Its CEO?
    Simply Wall St.

    Is Intuitive Surgical, Inc. (NASDAQ:ISRG) Overpaying Its CEO?

    Gary Guthart became the CEO of Intuitive Surgical, Inc. (NASDAQ:ISRG) in 2010. This report will, first, examine the...

  • Hedge Funds Have Never Been This Bullish On Intuitive Surgical, Inc. (ISRG)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Intuitive Surgical, Inc. (ISRG)

    Coronavirus is probably the 1 concern in investors’ minds right now. It should be. On February 27th we publish an article with the title "Recession is Imminent: We Need A Travel Ban NOW". We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

  • Urbem's 'Quality Strategy' Series: Reputation-Based Moat
    GuruFocus.com

    Urbem's 'Quality Strategy' Series: Reputation-Based Moat

    A valuable intangible asset in the mission-critical space Continue reading...

  • Here's Why You Should Invest in Intuitive Surgical Stock Now
    Zacks

    Here's Why You Should Invest in Intuitive Surgical Stock Now

    Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, stiff competition remains a woe.

  • These companies are spending billions so robots can perform surgery without a doctor in the room
    MarketWatch

    These companies are spending billions so robots can perform surgery without a doctor in the room

    Scientists are excited about the potential for artificial intelligence, improved connectivity, and other technological advancements to make robotic surgery more accurate and accessible.

  • Medical Products Industry Outlook: Growth Prospects Bright
    Zacks

    Medical Products Industry Outlook: Growth Prospects Bright

    Medical Products Industry Outlook: Growth Prospects Bright

  • Why Intuitive Surgical, Ping Identity Make MarketSmith's Growth 250 Near Pivot Stock List
    Investor's Business Daily

    Why Intuitive Surgical, Ping Identity Make MarketSmith's Growth 250 Near Pivot Stock List

    The MarketSmith Growth 250 Near Pivot stock list helps investors easily identify top stocks near potential buy points.

  • Intuitive Surgical Making A Recovery
    Investor's Business Daily Video

    Intuitive Surgical Making A Recovery

    Decelerating sales and earnings growth on Jan. 23 led to a slide in Intuitive Surgical. The surgical robotics maker took a 10% breather and is right back to new high territory. While there has been a deceleration what is notable is how stable the earnings are stability factor of 3 (lower is better). Not just the systems making up revenue base, 52% of it comes from instruments and accessories. As more procedures are done using the DaVinci system, those one-time tools will bring more to the top line as well.

  • Goldman Sachs Has New Stock Plays for Healthcare Fans
    TipRanks

    Goldman Sachs Has New Stock Plays for Healthcare Fans

    When looking at the healthcare industry, one sector in particular has been booming: the medtech space. Over the past five years, this area of the market has outpaced the S&P 500, with the large-cap sector index achieving a CAGR of 13%-plus versus the index’s 11%-plus CAGR.The source of this impressive growth? According to research from investment banking firm Goldman Sachs, the “durability” of this group of stocks fueled the strong performance. Highlighting organic sales growth, analyst Amit Hazan notes that from 2009 through 2015, a period that followed the 2008 recession and included 2015’s healthcare reform, “earnings growth for the group remained robust and never dropped below the high single digit-plus range.”Looking forward, the Goldman Sachs analyst argues that “incremental contribution from a slew of new product innovations within robotics, cardiology, diabetes and other key subsectors and continued regional expansion into faster growing emerging markets” will drive 6%-plus top line organic growth in 2020 and 2021.With this in mind, the analyst pointed to three medtech stocks as being especially compelling in a recent research report, kicking off his coverage of each with a Buy recommendation. Using TipRanks’ Stock Comparison tool, we were able to take a closer look at the picks by lining up the tickers alongside each other.Intuitive Surgical Inc. (ISRG)Earning a coveted spot on Goldman Sachs’ Conviction List, Intuitive Surgical has been at the forefront of robot-assisted surgery, with its da Vinci surgical system being one of the first robotic-assisted systems to receive FDA approval for general laparoscopic surgery. As of 2018, over six million surgeries had been performed using the technology all over the world. After posting a gain of 22% over the last six months, the firm believes that there’s more to come in 2020.Weighing in on ISRG, Hazan points out that surgical robotics adaption is ramping up, and as a result, the total market is expected to triple by 2030. Additionally, while there could be a competitive impact from Medtronic and Johnson & Johnson, the four-star analyst thinks there will be a “greater benefit via market expansion than risk to ISRG’s share from competition.” This combined with new geographic drivers specifically in China should put growth at a steady 18%-plus.Adding to the good news, Hazan expects annual growth contribution from new products to accelerate thanks to the release of its da Vinci Sp, Ion flex diagnostic platform, IRIS augmented reality and several new advanced stage instruments in 2020 and 2021. A new robotics system could also be unveiled within the coming 12 to 18 months.Based on the above factors, earnings could get a significant boost. “A combination of solid top line growth, which slightly leverages OpEx, and a very strong balance sheet should result in consistent high teens earnings growth. Hence, our sales/EPS estimates come in well above the Street,” Hazan commented.In line with his bullish take, the Goldman Sachs analyst initiated coverage by publishing a Buy rating along with a $725 price target. Should the target be met, a 12-month gain of 20% could be in the cards. (To watch Hazan’s track record, click here)Like Hazan, other analysts like what they’re seeing. With 9 Buy ratings and a single Hold assigned in the last three months, the word on the Street is that ISRG is a Strong Buy. While less aggressive than Hazan’s forecast, the $668.67 average price target still implies upside potential of 11%. (See Intuitive Surgical stock analysis on TipRanks)Varian Medical Systems (VAR)Using data and technology, Varian Medical Systems has helped advance radiotherapy, radiosurgery and many other vital cancer-fighting tools. While some investors have been concerned by its inconsistent quarterly performances, Hazan believes that its medium-term growth story is “healthier” than it has been.The analyst expects the company to sustain oncology order growth in the high single digits or low double digits based on Ethos, Halcyon, HyperArc, several new software offerings and new EM opportunities in both China and India. As a result, Hazan tells investors that the company is in a stronger position than it was at any point during the last ten years. Additionally, VAR’s installed base growth has been gaining steam and it has been expanding its MSD. This in turn has enhanced its opportunities in terms of both software and service, with half of revenue now recurring.On top of this, the company has been diversifying through new interventional oncology efforts. “While not very material quite yet, we expect this new segment to grow faster than the corporate average, be accretive to margins and earnings, and to diversify the Varian portfolio into new oncology channels and additional recurring revenue. We expect further investments into these markets, and believe it will be increasingly meaningful in the years ahead,” Hazan stated.Despite the fact that operating margin swing has hampered the stock, Hazan points out that in the next few years, there could be a leverage opportunity. “As Halcyon ramps, oncology GM should improve, while service and software mix should also drive a benefit. The Proton margin drag should diminish as service sales ramp, while we expect recent M&A will increasingly be accretive each year,” he explained.It should come as no surprise, then, that Hazan decided to side with the bulls, initiating coverage with a Buy rating. At $171, the price target implies shares could surge 16% in the next 12 months.In general, the rest of the Street is on the same page. 5 Buys and 1 Hold coalesce into a Strong Buy consensus rating. Based on the $159.67 average price target, the upside potential comes in at 9%. (See Varian Medical stock analysis on TipRanks)Stryker Corporation (SYK)Thanks to its cutting-edge products and services in orthopedics, medical and surgical and neurotechnology and spine that help improve patient and hospital outcomes, Stryker has earned its reputation as one of the top medtech players. As the Goldman Sachs analyst is calling for another year of substantial top line growth, it’s no wonder investors are excited.Based on Hazan’s estimates, organic growth could hit 8%-plus again in 2020. This is higher than Wall Street’s estimate as he thinks ortho robotic market growth and the contribution from new products within MedSurg and Neurotech appear somewhat under-modeled. He also sees less risk in store for SYK in the next year compared to other big growth companies.While acknowledging that he’s somewhat concerned about a possible near-term disruption to the extremities sales force, Hazan still thinks organic growth in the orthopedic division will remain strong and that MAKO-driven share gains as well as a surgery day tailwind can fuel gains. “More broadly, we are bullish on the ortho robotic market for the next few years, with the US installed base reaching 3,500 by 2025 (a 20%-plus CAGR) and SYK maintaining a dominant share. In the medium-to-long term, we expect new robotic opportunities to help SYK’s hips, spine and extremities too,” he noted.In addition, he pointed out, “Medical where strong capital trends and new products should help drive upside versus expectations. In Spine, growth improvement is very likely as K2M turns organic, but further integration risk as well as new competition from robotics suggest downside risk. Separately, Neurotech again looks poised for above-Street results as new Aspiration product intros take hold.”This played into Hazan’s conclusion that a stronger valuation is on the horizon as investor confidence continues to improve. It follows, then, that the analyst started his coverage of SYK at a Buy and attached a price target of $248. This conveys his belief that SYK could rise 12% in the year ahead.Looking at the analyst ratings breakdown, 7 Buys and 4 Holds add up to a Moderate Buy Street consensus. The $238.70 average price target puts the upside potential at 8%. (See Stryker stock analysis on TipRanks)

  • What Does Intuitive Surgical, Inc.'s (NASDAQ:ISRG) Share Price Indicate?
    Simply Wall St.

    What Does Intuitive Surgical, Inc.'s (NASDAQ:ISRG) Share Price Indicate?

    Let's talk about the popular Intuitive Surgical, Inc. (NASDAQ:ISRG). The company's shares saw a double-digit share...

  • Intuitive Acquires Orpheus Medical to Expand Informatics Platform for Hospitals
    GlobeNewswire

    Intuitive Acquires Orpheus Medical to Expand Informatics Platform for Hospitals

    Intuitive (ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced it has acquired privately held Orpheus Medical to deepen and expand its integrated informatics platform. Orpheus Medical provides hospitals with information technology connectivity, as well as expertise in processing and archiving surgical video. “The addition of Orpheus will provide customers —including surgeons, patient care teams and hospitals—with ready access to and a deeper understanding of their data, which we believe may help our customers improve patient outcomes and lower total treatment costs,” said Julian Nikolchev, Intuitive’s senior vice president of corporate development and strategy.

  • Intuitive Announces Retirement of Board Chair Lonnie M. Smith; Dr. Craig H. Barratt Succeeds Smith as New Chair
    GlobeNewswire

    Intuitive Announces Retirement of Board Chair Lonnie M. Smith; Dr. Craig H. Barratt Succeeds Smith as New Chair

    Intuitive (ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that Lonnie M. Smith has decided to retire from the company’s board of directors when his term ends at the company’s 2020 annual meeting of stockholders, currently scheduled for April. Mr. Smith will join the board of directors of the Intuitive Foundation after his retirement. Intuitive’s board of directors elected Dr. Craig H. Barratt to succeed Mr. Smith as chair effective as of the date of the company’s 2020 annual meeting of stockholders.

  • Here's Why You Should Add HealthEquity (HQY) to Portfolio Now
    Zacks

    Here's Why You Should Add HealthEquity (HQY) to Portfolio Now

    Solid prospects in the HSA industry consistently drive HealthEquity (HQY).